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SUMMARY
Given the complex nature of Alzheimer’s disease (AD), a cell-based model that recapitulates
physiological properties of the target neuronal population carries significant value in discovering
improved drug candidates and chemical probes for uncovering disease mechanisms. We
established phenotypic neuronal assays for biogenesis and synaptic action of amyloid β-peptide
(Aβ) based on embryonic stem (ES) cell-derived neurons (ESNs). ESNs enriched with pyramidal
neurons were robust, scalable and amenable to a small molecule screening assay, overcoming
apparent limitations of neuronal models derived from human pluripotent cells. Small molecule
screening of clinical compounds identified four compounds capable of reducing Aβ levels in ESNs
derived from the Tg2576 mouse model of AD. Our approach is therefore highly suitable for
phenotypic screening in AD drug discovery and has the potential to identify therapeutic candidates
with improved efficacy and safety potential.
INTRODUCTION
Elevation and accumulation of amyloid β-peptide (Aβ) in brain are early and necessary steps
in pathogenesis of Alzheimer’s disease (AD), preceding all known clinical and pathological
phenotypes of the disease, including memory and cognitive decline, by at least a decade
(Hardy and Selkoe, 2002; O’Brien and Wong, 2011; Zheng and Koo, 2011). Aβ is liberated
from β-amyloid precursor protein (APP) by membrane-bound proteases, β-secretase
(BACE1) and γ-secretase (Hardy and Selkoe, 2002; O’Brien and Wong, 2011; Zheng and
Koo, 2011). The majority of current therapeutic strategies have focused on developing
potent small molecule inhibitors for targeting well-defined enzymatic targets, including the
secretase enzymes. Despite initial promise, the majority of these approaches suffered major
setbacks in late stage clinical trials (Mangialasche, 2010). Therefore, model systems and
biomarkers that can better predict the efficacy and safety of therapeutic candidates in human
clinical trials have become increasingly important.
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Cell types historically used in AD drug discovery, such as immortalized or genetically
transformed neuronal lines, lack complete phenotypic properties of primary neurons.
Dissociated primary neuronal cultures, though a better physiological model compared to cell
lines, have major limitations due to survival time in culture, cellular heterogeneity and
inability for large scale production (McNeish, 2004; Pouton and Haynes, 2007). Stem cell
technology furnishes a novel opportunity for the generation of a physiologically relevant
disease model using directed differentiation of stem cells into the optimal model cell type
suitable for functional study and drug discovery (McNeish, 2004; Pouton and Haynes, 2007;
Rubin and Haston, 2011).
Creation of a human neuronal model derived from human embryonic stem (ES) cells or
patient-derived induced pluripotent stem (iPS) cells would ultimately serve as the ideal
disease model, eventually able to predict drug responsiveness in cells originating from the
patient’s own tissue (Yamanaka and Blau, 2010; Jang et al., 2012) However, despite great
promise, productive and reliable use of human ES or iPS cells in drug discovery remains
challenging (Ebert and Svendsen, 2010; Han et al., 2011). For drug screening applications
such as high throughput screening (HTS), human ES and iPS protocols require laborious
maintenance which make automation and differentiation into functional neurons challenging
(Ebert and Svendsen, 2010). Furthermore, genetic and epigenetic variability among patients
may influence pharmacological responsiveness, hindering the practical application of stem
cells from human patient origin for drug discovery (Han et al, 2011). In contrast to human
stem cells, mouse ES (mES) cells harbor several notable advantages for bioassays and drug
discovery applications, including the relatively homogenous nature of differentiated cells,
potential derivation from disease models and convenient expandability (Pouton and Haynes,
2007). It has been shown that mES cells can be differentiated into specific neuronal
subtype(s), including pyramidal neurons, a significantly vulnerable neuronal population in
AD (Mann, 1996; Morrison and Hof, 2002).
To establish an AD-centric primary neuronal model, we developed phenotypic cell-based
assays for the biogenesis and synaptic action of Aβ using mouse ES cell-derived neuronal
cultures enriched in functional pyramidal neurons. We isolated ES cells from a mouse model
of the disease, Tg2576 which harbors human APP with the Swedish mutation (APPsw). To
validate application of mouse embryonic stem cell-derived neurons (ESNs) we screened a
library of clinical compounds and identified four compounds capable of reducing Aβ levels.
Our neuronal model is therefore highly suitable for phenotypic screening in AD drug
discovery and has the potential to enhance the predictive value of cell-based screening
assays for lead compounds with a higher probability of surviving advanced rounds of vetting
for efficacy and diminished toxicity.
RESULTS
Characterization of Pyramidal Cell Enriched ESN Cultures
A neuronal culture highly enriched in pyramidal neurons was produced by directed
differentiation of mES cells by modifying published protocols (Figure 1A) (Bibel et al.,
2004; Bibel et al., 2007). Neuronal morphology was apparent after 1 day in vitro (DIV) and
the majority of cells displayed neuronal morphology by DIV 5 (Figure 1A). By DIV 7
neuronal proteins including neuronal β-tubulin III (TUJ-1) and pyramidal neuron marker
EMX1 were expressed indicating a highly homogenous neuronal population enriched in
pyramidal neurons (Figures 1B and 1D) (Chan et al., 2001). Glial cells, identified by glial
fibrillary acidic protein (GFAP) were only rarely observed (Figures 1C and 1D). Neuron
specific proteins, neuronal β-tubulin (TUJ-1) and synaptophysin, as well as glutamatergic
neuronal proteins, TrkB and CaMKIIα, increased from DIV 1-7 and there was a gradual
decline in the levels of the p75 neurotrophin receptor (p75NTR) consistent with maturing
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pyramidal neurons (Figure 1E) (Buck et al., 1988). The subcellular distribution of
endogenous pre-synaptic synaptophysin and post-synaptic PSD-95 as adjacent puncta along
dendrites recapitulated mature synapses in primary neurons (Figure 1F). Electron
microscopy (EM) analysis revealed that both presynaptic vesicles as well as postsynaptic
densities were apparent in this culture (Figure 1G). Expression of PSD-95 and
synaptophysin was evident by Western analysis by DIV 14 (Figure 1H).
Modeling Aβ-induced synaptic alterations in ESNs
Oligomeric Aβ induces both structural and functional alterations at synapses in cultured
neurons (Pozueta et al., 2012). To model this using mouse ESNs, we examined the effects of
Aβ treatment on synaptic morphology and changes in cell signaling events indicative of
synaptic plasticity. Synapse loss is documented in AD mouse models and after treatment of
neurons with oligomeric Aβ, correlating with the loss of immunoreactivity of PSD-95, a
postsynaptic protein (Gylys et al., 2004; Roselli et al., 2005; Cerpa et al., 2010). In ESNs,
oligomeric Aβ treatment decreased PSD-95 puncta count, fractional area and total area but
synaptophysin puncta, a presynaptic protein, remained unchanged (Figures 2A-2F) (Hu, et
al., 2003; King ad Arendash, 2002; Jacobsen et al.,2006). Aβ treatment also triggers
morphological defects in synaptic spines including reduction in dendritic spine density
(Hsieh et al., 2006; Shankar et al., 2007; Lacor et al.,2007). Diolistic labeling of neurons
(Moolman et al., 2004; McIntire et al., 2012) revealed that treatment of ESNs with Aβ
oligomers reduced spine density (Figure 2G, H). After Aβ oligomer treatment, spine length
increased modestly and slightly decreased dendritic diameter (Figures 2I and 2J) (Calabrese
et al., 2007; Lacor et al., 2007). In addition to morphological spine changes, at a functional
level, Aβ has been shown to induce characteristic molecular changes in neurons, including
suppressed phosphorylation of cyclic AMP response element binding protein, CREB, a
memory-associated transcription factor (Vitolo et al., 2002; Snyder et al., 2005). In ESNs,
Aβ oligomer treatment prevented NMDA stimulation dependent phosphorylation of CREB
(pCREB) (Figures 2K and 2L). Treatment of ESNs with Aβ oligomer at high concentrations
led to neuronal death (Figure S1).
Expression of Secretase Components in ESNs
To determine if ESNs would effectively model Aβ biogenesis, we determined expression of
enzymatic components of APP processing. ESNs express the β-site APP cleaving enzyme
(BACE1) at later stages of differentiation but not in ES cells (Figures 3A and 3C) (O’Brien
and Wong, 2011; Zheng and Koo, 2011). In contrast, PS1 was detected in mES cells
consistent with its described role in development (Figure 3B) (Wong et al., 1997). Further,
APP and BACE1 were enriched in the late endosomal compartment enriched for syn6 and
rab11 and de-enriched in early endosomes containing early endosomal protein A1 (EEA1)
consistent with published distribution in cultured primary neurons (Figure 3C) (Tang, 2009;
Finan et al., 2011; Wen et al., 2011).
Genetic Modeling of Expression of FAD-associated APP and PS1 in ESNs
To model familial AD (FAD), wild type ESNs were infected with APPsw lentivirus and APP
processing was analyzed. Treatment of infected ESNs with BACE1 inhibitor (BSI) (Stachel,
2006) reduced secretion of sAPPβ, Aβ40 and Aβ42 while treatment with γ-secretase
inhibitor (GSI) (Seiffert, 2000) inhibited Aβ40 and Aβ42 secretion without affecting the
levels of secreted APP β-cleaved fragment (sAPPβ) or secreted APP α-cleaved fragment
(sAPPα) (Figures 3D and 3F). Consistent with previous studies in cell models and mouse
brain, C-terminal fragments (CTFs) resulting from APP cleavage, accumulated in response
to GSI treatment (Figure 3D) (Hardy and Selkoe, 2002; O’Brien and Wong, 2011; Zheng
and Koo, 2011; Landman et al., 2006; Okada et al., 2010).
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To model PS1-linked FAD phenotypes in ESNs, three different FAD mutant PS1 transgenes
(ΔE9, M146V, and L286V) were elctroporated into mES cells to produce ES lines stably
expressing the mutants. Resulting stable mES cells were subjected to directed differentiation
into pyramidal neurons. A representative Western blot shows the PS1 transgene and normal
neuronal protein expression in ESNs derived from these clonal mES cell lines (Figures 3G
and 3H). An increase in the Aβ42/ Aβ40 ratio, a key pathogenic phenotype associated with
PS1 FAD (O’Brien and Wong, 2011; Zheng and Koo, 2011) was observed in ESNs
expressing ΔE9 M146V, and L286V mutant forms of PS1 after APPsw lentiviral infection
(Figure 3I).
ESNs from Tg2576 Mouse Model of AD
In order to achieve robust and reproducible neuronal expression of human APP, mES cells
were isolated from the inner cell mass of blastocysts from a well characterized mouse model
of AD, Tg2576 (Hsiao et al., 1996). ESNs from Tg2576 showed normal neuronal
differentiation by morphology and neuronal protein expression (Figures 4A and 4B),
comparable to neuronal differentiation of wild-type ES cells. Transgene-derived human
APPsw was expressed at DIV 1-7, but little expression was detected in the undifferentiated
mES cells (Figure 4B). APP processing at DIV 7 was sensitive to BSI, GSI and an α–
secretase inhibitor, TAPI-2. APP CTF expression increased in response to GSI treatment,
but levels of neuronal proteins synaptophysin, CaMKIIα and neuronal β-tubulin did not
change with any pharmacological treatment (Figure 4C). Soluble sAPPα and sAPPβ were
reduced by TAPI-2 and BSI treatment respectively (Figure 4D). Further, human Aβ40 and
Aβ42 were reduced by treatment of neurons with BSI and GSI as predicted (Figures 4E and
4F) (Stachel, 2006; Seiffert, 2000).
High Throughput Screening Assay for Aβ in Tg2576 ESNs
High-throughput screening (HTS) using a miniaturized assay allows rapid and parallel
examination of the bioactivities of large numbers of compounds. To accommodate HTS in
ESNs, we miniaturized an Aβ detection assay using Tg2576 ESNs cultured in a 96 multi-
well plate. We determined the optimal cell density and assay parameters to optimize
suitability and robustness for HTS application. The optimal cell density of 1.5×105 cells/cm2
maximized the cell viability signal (Figures 5A and 5C). Two parameters commonly used to
evaluate the robustness of a HTS assay are the coefficient of variance (%CV) and Z’ factor
(Inglese et al., 2007). Typically, an assay with %CV value <15% and Z’ factor >0.5 is
considered a robust assay suitable for HTS (Inglese et al., 2007). At the plating density of
1.5×105 cells/cm2, with 5 replicate wells, both the %CV (Figure 5B) and Z’ factor (Figure
5C) were optimized. Using the optimized 96 well platform, ESNs derived from the Tg2576
mouse model displayed characteristic inhibitor response kinetic profiles for both BSI and
GSI (Figures 4E and 4F) (Stachel, 2006; Seiffert, 2000). Values of %CV for Aβ40 and Aβ42
indicated acceptable variance for signal detection (Inglese et al., 2007). Additional metrics
including signal to noise (S:N), signal to background (S:B) and signal window also indicated
detection of Aβ40 and Aβ42 was sufficiently higher than variance of the assay (data not
shown).
Identification of Clinical Compounds that Reduce Aβ Secretion in ESNs
To fully validate the ESNs-based assay, we screened for inhibitors of Aβ secretion using the
NIH clinical collection (NCC) which consists of 446 small molecules that have a history of
use in human (Noorbakhsh et al., 2009). Compounds were identified as hits if they reduced
Aβ40 by 40% and deviated 4 standard deviations from the average value of negative
controls (Figure 6A) but maintained cell viability within 2 standard deviations of control
(Figure 6B). The most potent hits identified were amiridine, icariin, phenelzine and
progesterone (Figure 6C). The compounds were obtained from an independent source,
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activity was confirmed and they were subjected to IC50 determination (Figure 6D). To
investigate the possible mechanisms of the Aβ-reducing activity of these compounds,
alterations in APP processing were determined in response to compound treatment. Icariin,
phenelzine and progesterone reduced sAPPβ levels, suggesting that these compounds may
modulate the activity of BACE1 (Figures 6E and 6F). None of the compounds significantly
affected levels of sAPPα or full length APP (Figures 6D, 6G and 6H). Aβ40 was confirmed
to be reduced by the hit compounds (Figure 6I).
Pharmacological Response of Hit Compounds in ESNs and Cell Lines
An advantage of phenotypic screening in ESNs is the preservation of the cellular context of
physiological neurons compared to commonly used cell-based screening assays typically
based on transformed cell lines. Therefore, we determined the ability of hit compounds to
exert Aβ-lowering activity in APP, PS1 and BACE1 expressing cell lines. Interestingly,
icariin, phenelzine and progesterone did not significantly reduce Aβ secretion in any of the
three alternate cell lines we tested, including Neuro2a expressing APPsw, CHO expressing
APP and mutant PS1 (ΔE9), and SH-SY5Y cells expressing BACE1 and APP (Figure 7).
Amiridine reduced Aβ secretion in the SH-SY5Y cell line however, Aβ-reducing activity
was not observed in Neuro2a or CHO cell lines (Figure 7).
DISCUSSION
Our current study presents practical applications of mouse ESNs for AD and CNS drug
discovery research. ESNs serve as an infinite source of neurons which functionally and
morphologically recapitulate pyramidal neurons as well as harbor the appropriate machinery
for APP processing and synaptic function. We show that ESNs can be cultured and assayed
in a platform suitable for drug screening. Using ESNs from the Tg2576 mouse model of AD,
we established and validated a high throughput screening (HTS) platform for an Aβ
detection assay and also provided examples of how this platform can be used to probe
various key biological and pathophysiological pathways in intact primary neurons, such as
analyses of alterations in synaptic function and structure, and APP processing. It is plausible
that our ESN platform is also applicable to parallel detection of multiple β-amyloid
phenotypes described in this paper, in addition to other AD-associated phenotypes such as
tau-associated abnormalities. Thus, to address the complex biological mechanisms
underlying AD, our model uniquely permits the investigation of druggable pathways or
networks in intact neurons (Noorbakhsh et al., 2009).
The mouse ESN model has appreciably enhanced suitability for HTS compared to human
ES and iPS cell-derived neurons. In general, much longer expansion and differentiation
periods are required for ESNs and iPS-derived neurons, which typically require 21+ days for
differentiation and up to 5 weeks for maturation in culture to display desired phenotypes
(Barker, 2012; Dhara and Stice, 2008; Schwartz et al.,2008). Thus, mouse ES cells and
ESNs harbor an advantage over human systems for ease of expandability in a practical
amount of time for automation (Erceg et al., 2009; Kim et al., 2011; Nistor et al., 2011).
Furthermore, it is difficult to obtain relatively homogenous neuronal populations from
human pluripoent cells in contrast to mouse ESNs implying that our mouse ESN-based
approach is more suitable for quantitative detection and assays owing to relatively
homogenous and reproducible neuronal cultures (Engle and Puppala, 2013; Ebert and
Svendsen, 2010; Han, 2011) Human iPS cells from AD patients have recently been
successfully differentiated into neurons displaying several expected phenotypes including
elevated Aβ (Yagi et al., 2011; Israel et al., 2011). However, iPS cell-derived neurons from
one sporadic AD patient lacked the Aβ increase altogther, highlighting the inherent
variability among patient derived iPS cells due to differences in genetic background
compounded with inherent variability among clones from the same patient (Israel et al.,
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2011; Choi and Tanzi, 2012; Ooi et al., 2013). Further, since AD has a mixed etiology,
selecting appropriate control lines for iPS is challenging considering the variability in
genetic background of each patient (Barker, 2012; Choi and Tanzi, 2012). In contrast, mouse
ES cell lines can be harvested from the numerous existing mouse models, giving rise to
disease models and near-clonal appropriate controls. Genetic and epigenetic integrity in iPS
cells may be compromised by insertional defects owing to the integration of ectopic
transcription factors (Han et al., 2011; Papp and Plath, 2011). Synapse loss, a critical feature
in AD correlating with disease severity, was not observed in recent publications on iPS from
AD patients, perhaps due to limited culture duration (Yagi et al., 2011; Choi and Tanzi,
2012), however, mouse ESN display robust synapse formation as well as Aβ-triggered
synapse loss (Figure 2). Thus, mouse ESNs uniquely harbor both phenotypic relevance and
HTS adaptability. Though mouse ESN are favorable for HTS, human derived ESN and iPS
derived neurons currently hold high value for secondary confirmatory studies for compound
efficacy and toxicity in the human genetic background.
The four most potent hits identified in our screen are known CNS drugs. Amiridine belongs
to the class of aminopyridine acetylcholinesterase inhibitors including tacrine, which have
been used in the clinic for the symptomatic treatment for AD (Braginskaya et al., 2001;
Yoshida and Suzuki, 1993). An interesting future investigation would be to determine
whether the Aβ lowering activity is a common property of all aminopyridine compounds in
this drug class and if this activity potentially influences clinical variables. Phenelzine
belongs to a class of drugs, the monoamine oxidase inhibitors (MAOI), which have been
studied for potential clinical use in AD, based on their ability to promote neurotransmission
and improve cognition (Freedman et al., 1998; Mangoni et al., 1991; Sano et al., 1997; Volz
and Gleiter, 1998). We found that phenelzine reduced Aβ and sAPPβ secretion suggesting
that this compound may reduce Aβ through the inhibition of BACE1 in neurons. In the
previous studies, derivatives of this class of drug have been reported to inhibit γ-secretase
activity and stimulate sAPPα production in cell lines (Lee et al., 2010; Weinreb et al., 2009;
Yodim et al., 2003)., Thus, it is conceivable that phenelzine confers Aβ-reducing activities
through multiple mechanisms involving both β- and γ-secretase pathways through cellular
target(s) have not yet been identified. Icariin has been reported to reduce Aβ-induced
synaptic and cellular deficits (Li et al., 2010; Zeng et al., 2010) and ameliorate memory
impairment in Aβ treated rats and a mouse model of AD (Nie et al., 2010; Urano and Tohda,
2010). Icariin has also been reported to reduce the expression of BACE1 (Nie et al., 2010).
Consistent with its reported role on BACE1, we found that icariin reduces secretion of
sAPPβ which may have contributed to cognitive improvements observed in previous mouse
model studies. Lastly, our screen identified progesterone as a Aβ-reducing compound. In
previous in vivo studies, progesterone was shown to reduce amyloid load and improve
cognitive performance of AD mouse models (Carroll et al., 2010; Frye and Walf, 2008).
Since progesterone lowered sAPPβ, Aβ40 and Aβ42 production in neurons, it is conceivable
that Aβ-reducing activity may underlie the observed rescue of pathological and behavioral
changes in mouse models of AD. Collectively, our approach therefore could be useful in
evaluating potential of known drugs for a new use in AD in the context of phenotypically
intact neurons as well as screening for novel small molecules.
EXPERIMENTAL PROCEDURES
Directed differentiation of mouse embryonic stem cells to pyramidal neurons
mES were maintained for two passages on mouse embryonic fibroblast (MEF) feeder cells
in the presence of Leukemia Inhibitory Factor (LIF) (Millipore). For embryoid body (EB)
formation, mES were deprived of MEFs for two passages. EB were grown in suspension for
8 days and in the presence of retinoic acid (RA) for the last 4 days prior to plating as
neurons. Optimized neuronal media containing N2 supplement (Invitrogen) was used for the
McIntire et al. Page 6













first 2 days after plating and B27 (Invitrogen) supplemented media was used for the duration
of the culture. Detailed media composition and protocols are found in Supplemental
Experimental Methods.
Analysis of synaptic proteins, morphology and spine density
After DIV21, ESN were treated with 200nM Aβ oligomer prepared as previously described
(Dahlgren et al., 2002; McIntire et al., 2012) for 24 hours then fixed in 4%
paraformaldehyde and 4% sucrose in PBS for 20 minutes. PSD-95 (Thermo Scientific) and
synaptophysin (S-physin) (Epitomics) antibodies were used and detected with Alexa tagged
secondary antibodies (Molecular Probes). For spine analysis, after fixation, neurons were
labeled with DiI (Molecular Probes) as previously described (Moolman et al., 2004;
McIntire et al., 2012). Images were collected with an inverted Olympus microscope with
100x objective using Nikon C2 confocal laser microscope system. For spine analysis, 0.5μM
z-sections were taken at 3x zoom. Images were stacked, used for 2-D projection with ImageJ
1.4g software (NIH), and measured with the segmented line tool. For particle analysis, the
RGB colors were split, threshold was set for each image, and the analyze particles tool was
used.
Phospho-CREB detection
Neurons were grown to maturity and pre-treated for 1 hour in the presence or absence of Aβ
oligomer preparation. Subsequently, cultures were treated 10 minutes under stimulating
conditions (150mM, 5mM KCl, 2mM CaCl2, 30mM glucose, 10mM HEPES, pH7.4, 10μM
NMDA) (Synder et al., 2005) or non-stimulating conditions (120mM NaCl, 3mM KCl,
2mM CaCl2, 2mM MgCl2, 15mM glucose, 15mM HEPES, pH 7.4) in the presence or
absence of Aβ oligomer (Dahlgren et al., 2002). Protein was solubilized immediately in
Laemmli sample buffer and loaded (v/v) to 4-20% Tris/Glycine gel (Invitrogen). Protein was
separated using SDS-PAGE and quantitative Western blotting was accomplished using
infra-red secondary antibody (Rockland) detection with the Licor Odyssey Infrared Imager
with solid-state diode laser at 685 nm and 785 nm. Total CREB primary antibody was from
Santa Cruz Biotechnology and phospho-CREB (S133) primary antibody was from
Invitogen.
Subcellular Fractionation
Differentiated mouse embryonic stem cells were homogenized using a ball-bearing
homogenizer in homogenization buffer (0.25M sucrose, 10mM Tris, pH7.4, 2mM MgAC,
and 0.5 mM EDTA, supplemented with protease inhibitors (Roche)). Homogenate was
loaded onto a 0.25M – 2M sucrose step gradient and centrifuged for 2.5h at 39,000rpm at
4°C. Ten fractions were collected and analyzed by Western blotting. Primary antibodies
used were: anti-sortilin (BD Biosciences), anti-BACE1 (Zhoa et al., 2007), anti-APP-
CTmax (Landman et al., 2006; Okada et al., 2010), anti-syn6 (BD Biosciences), anti-EEA1
(Affinity BioReagents) and anti-Rab11 (BD Biosciences).
Lentiviral Expression of APPsw in ESNs and generation of FAD mutant PS1 stable ES cell
lines
To model human APP processing, neurons were infected with APPsw lentivirus for 24 hours
and 48 hours after initial infection, treated with BACE inhibitor IV (BSI) (Calbiochem) or γ-
secretase inhibitor (GSI) (Calbiochem) for 24 hours. Uninfected neurons were treated with
0.1% saponin (Sap) as a positive control for loss of cell viability. To generate stable lines of
mES cells expressing PS1 wild-type and FAD variants 3×106 ES cells were resuspended in
Nucleofector solution (Amaxa Neucleofector, Lonza) and mixed with 20 μg plasmid
carrying human wild-type or FAD mutant PS1 and neomycin resistance in the pcDNA3.1
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vector. Cells were electroporated using program A-13 (Amaxa), resuspended, plated on
feeder cells and subjected to G418 (250-500 μg/ml) selection 24 hours after electroporation.
Analysis of APP processing
At DIV 12-30, neurons were infected with lentivirus carrying the Swedish variant of human
APP (pLenti6/hAPPsw). After 24 hrs, cell medium was changed and 48 hours after infection,
cells were treated with secretase inhibitors. Conditioned media was collected after 24 hrs
and the levels of Aβ42 and Aβ40 were determined using sandwich ELISA (Invitrogen)
according to the manufacturer’s protocol. Total protein levels were determined by BCA
protein assay (Pierce). Total Aβ was detected by immunoprecipitating conditioned medium
with 6E10 (Covance) or 7N22 (Invitrogen) antibodies, running samples on NuPAGE gels
and detected by quantitative Western blotting with 6E10 antibody. Full-length APP was
detected by Western blot analysis using 6E10 (Covance) or polyclonal antibody against the
C-terminus of APP (APP-CTmax) (Landman et al., 2006; Okada et al., 2010). For detection
of of sAPPβ and sAPPα conditioned medium was harvested 24 hours after a media change.
Immunoprecipitation of sAPPβ was performed using sβsw antibody (Figure S2). Protein G
plus/Protein A agarose suspension (Calbiochem) was used to precipitate the antibody-
protein complex. The immunoprecipitate was subjected to SDS-PAGE followed by Western
blot detection using 22C11 (Chemicon) or LN27 (Covance). sAPPα was
immunoprecipitated with 6E10 and detected on Western blot with LN27. BACE inhibitor
IV, compound E and TAPI-2 were from Calbiochem.
Isolation of ES cells from a mouse model of AD
Tg2576 mice were outbred strain of Swiss Webster × B6D2F1 which is a C57BL/6 × DBA/
2 F1 cross harboring the APP transgene with the Swedish mutation under the control of the
prion promoter (Hsiao et al., 1996) C57BL/6 females 23 days old were induced for
superovulation with a standard protocol using intraperitoneal injection with pregnant mares
serum gonadotropin (PMSG) on day 1 and human chorionic gonadotropin (hCG) on day 3.
Immediately following the final injection, the female was mated with a male positive for the
APPsw transgene. After 3.5 days blastocysts were flushed from the uterus and cultured in
96-well feeder plate wells containing mitomycin C-treated MEF feeders in ES medium for
six days without medium change. Inner cell mass (ICM) outgrowth was disaggregated with
0.05% trypsin into small clumps and plated in one well of 24-well feeder plates. ES colonies
were apparent on day three after re-plating and ES cells were passaged upon confluence and
maintained as above. DNA was isolated using the DNeasy and Tissue DNA isolation kit
(Qiagen). ES lines harboring the transgene were identified using PCR based genotyping
protocol with primers against the human APPsw gene sequence (sense primer 1:
CCGAGATCTCTGAAGTGAAGATGGATG and antisense primer 2:
GTGGATACCCCCTCCCCCAGCCTAGACC).
Small molecule screen of clinical compound library for reduction of Aβ
ESNs were plated in 96 well black plates at a density of 1.5×105 cells/cm2 (45,000 cells/
well). After DIV 8, ESNs were treated with 10μM of each compound from a library of 446
clinically relevant compounds which have a history of use in human, the NIH clinical
collection (NCC) (NIH) for 24 hours in B27 media. Each plate of ESNs was treated
additionally with DMSO (negative control), and positive controls for Aβ reduction, BSI and
GSI using 6 replicates. After 24 hours, conditioned media was harvested and frozen at -80°C
until Aβ40 analysis using human specific ELISA (Invitrogen). The remaining cells were
subjected to cell viability assay CellQuanti Blue (BioAssay Systems). Compounds were
considered hits if they reduced Aβ40 by 40% compared to the negative control (DMSO) and
reduced Aβ40 by 4 standard deviations from the average value of the negative control but
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maintained cell viability. Cell viability was defined by maintenance of CellQuanti Blue
(BioAssay Systems) fluorescent signal within two standard deviations of the control treated
(DMSO) neurons. For confirmation studies, amiridine, phenelzine and icariin were obtained
from Sigma and progesterone was obtained from Tocris.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Scaling and optimizing primary neurons derived from mouse ES cells
• Modeling phenotypic assays using mouse ESNs for biogenesis and synaptic
action of Aβ
• Isolation and use of ES cells originating from a mouse model of AD
• Screen of clinical compounds and identification of Aβ-lowering small molecules
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Our current study describes practical applications of mouse embryonic stem (ES) cell-
derived neurons (ESNs) for AD and CNS drug discovery research. Our studies indicate
that ESNs could potentially replace dissociated primary neuron cultures as a cell-based
model for investigation of neurobiology and pathobiology relevant to AD. We also
demonstrated that ESNs from the Tg2576 mouse model of AD can be cultured and
assayed in a platform suitable for drug screening. Using this ESN-based assay, we
performed phenotypic screening assays and identified four interesting clinical
compounds for which Aβ-modulating effects have not been previously reported in
primary neurons. There is a growing demand for preclinical models that reliably predict
efficacy and safety prior to clinical trials. This demand can be met by specialized disease-
relevant cell types. For drug discovery applications, our system offers notable advantages
over human patient derived stem cells, which have limited expandability and phenotypic
variability. Thus, our model overcomes current challenges in phenotypic HTS assays in
neurons, bridging the gap between in vitro screening paradigms and translational drug
discovery and has great potential to lead to innovation in AD drug discovery by
furnishing pyramidal neurons amenable to screening and functional evaluation of
compound efficacy and toxicity in stem cell-derived primary neurons.
McIntire et al. Page 15













Figure 1. Directed Differentiation of mES Cells Into Pyramidal Cell-enriched Neurons
(A) Schematic of the differentiation procedure for mES cell derived neurons using primary
mouse embryonic fibroblasts (pMEF) and retinoic acid (RA) showing ES cells and ESNs at
DIV 5. (B) ES cell derived neuronal culture at DIV 7 co-labeled with neuronal β-tubulin III
(TUJ1) and EMX1 antibodies and DAPI to identify nuclei. (C) ES cell derived neuronal
culture at DIV 7 co-stained with GFAP antibody and TUJ1 antibodies and DAPI to identify
nuclei. (D) Quantification of cultures show only 6(±1.5) % of cells stained positive for
GFAP, while 68(±10)% cells were positive for EMX1 and 89.5 (±4)% cells were positive
for TUJ1. Scale bar represents 40μm. (E) Cultures increasingly express neuronal proteins
assessed by Western analysis using indicated antibodies. (F) Confocal images of DIV21
neurons derived from mES cells detect post-synaptic density protein PSD-95 and pre-
synaptic density protein synaptophysin which localize to adjacent puncta at higher
magnification. (G) Electron micrograph showing intact synaptic structures including post-
synaptic density and pre-synaptic vesicles in DIV 21 cultures. (H) PSD-95 and
synaptophysin (S-physin) detection by Western analysis.
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Figure 2. Modeling Aβ-associated Synaptic Abnormalities in ESNs
(A and B) At DIV 21 mES derived neurons were treated for 24 hours with DMSO control
(Ctrl) or Aβ42 oligomer, subsequently fixed and co-stained for synaptic proteins PSD-95
(green) and synpatophysin (S-physin) (red). Nuclei are labeled with DAPI (blue). PSD-95
and S-physin particles were analyzed using Image J software. (C-F) Quantification of
PSD-95 positive particles and S-physin positive particles using Image J software particle
analysis. (G) DIV 21 ESN were treated with control or Aβ42 oligomer, fixed, diolistically
labeled and imaged with confocal microscopy. (H-J) Spine density, length and dendrite
diameter were quantified using Image J software. (K) Phosphorylation of CREB was
detected with a pCREB specific antibody after no stimulation (NS) or NMDA stimulation
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(ST) of cultures with or without Aβ42 oligomer (Aβ) pretreatment. (L) Quantification of
CREB and pCREB using infrared quantitative Western blot imaging system with SEM
shown by error bars.
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Figure 3. ESNs Harbor Machinery for APP Processing and Recapitulate Phenotype Associated
with PS1 FAD
(A) APP and BACE1 expression in mES cells and ESNs at DIV 7, 14 and 21. (B)
Components of the γ-secretatse, PS1, APH-1, NCT and PEN2 detected by Western blot
analysis of the cell lysates using indicated antibodies. (C) Gradient centrifugation shows
APP and BACE1 are enriched in the late endosome compartment with Syn6 and Rab11 but
not at the top of the gradient with EEA1. (D) Western blot analysis of protein lysates from
mES cell derived neurons infected with Lentivirus harboring human APPsw expressing APP
and proteolytic fragents. Secreted APP fragments, sAPPβ and sAPPα, were
immunoprecipitated from conditioned media and APP and CTFs were detected in cell
lysates. (E-F) Aβ40 and Aβ42 were detected in conditioned medium using human specific
ELISA and values were normalized to protein lysate concentration. (G) Three different FAD
mutants of PS1 (ΔE9, M146V, and L286V) were introduced into mES cells which were
subsequently subjected to directed differentiation into pyramidal neurons. A representative
Western blot shows transgene expression in the neurons derived from these clonal mES cell
lines using an anti-human PS1 specific antibody (PS1-NT). (H) PS FAD-expressing cells
undergo normal directed differentiation into pyramidal neurons indicated by expression of
neuronal proteins. (I) ELISA detection of Aβ42 and Aβ40 from conditioned media of ESNs
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stably expressing PS-FAD mutants infected at DIV 7 or 14 with APPsw Lentiviral particles
resulted in enhanced ratio of Aβ42/Aβ40. Lentiviral gene transfer did not affect the viability
of ESNs (data not shown).
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Figure 4. Analysis of mES Cells and ESNs Isolated From Tg2576 AD Mouse Model
(A) Tg2576 mES-derived neurons identified by nuclear DAPI stain, express neuronal β-
tubulinIII (TUJ-1) (green) and pyramidal cell protein EMX1 (red). Scale bar represents
40μm. (B) Western blot analysis of protein lysates from Tg2576 mES-derived neuronal
culture harvested at indicated DIV express APP, cleaved APP fragments (APP-CTF) and
neuronal proteins synaptophysin, CamKIIα and neuronal β-tubulinIII (TUJ-1). α-Actin is a
loading control. (C) Cell lysates from DIV 7 Tg2576 ES-derived neurons treated with
indicated compounds were subjected to Western blot detection with 6E10 (APP-FL), APP-
CTmax (APP-CTF) and antibodies to indicated proteins. (D) Secreted sAPPα and APPβ
were immunoprecipitated from conditioned medium after treatment of Tg2576 ES-derived
neurons with the indicated compounds. (E, F) Secreted Aβ levels detected using human
specific Aβ40 or 42 ELISA kit. Aβ40 and Aβ42 show characteristic sensitivity to BSI and
GSI inhibition. IC50 values for the BACE1 inhibitor were 229.7nM and 28.1nM for Aβ40
and Aβ42 respectively. IC50 values for Compound E were 136.9pM and 102.2pM Aβ40 and
Aβ42 respectively. The Z’ factors were 0.85 for Aβ40 and 0.5 for Aβ42 indicating an
excellent assay for HTS.
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Figure 5. Miniaturization and Optimization of 96 Well Platform for Mouse ESNs
(A) DIV 8 Tg2576 ES-derived neurons were plated at increasing density in a 96 well plate
and subjected to a cell viability assay quantified in relative fluorescent units (RFU). (B)
%CV and (C) Z’ were calculated with increasing number of wells. The minimum %CV and
maximum Z’ are optimized at n=5 wells at a plating density of 1.5×105 cells/cm2 (arrows in
B and C).
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Figure 6. Screening NIH Clinical Collection (NCC) for Aβ Biogenesis
(A) DIV 7 Tg2576 ESNs plated in 96 well plate platform were treated with compounds from
the NCC compound collection for 24 hours and Aβ40 was detected in conditioned media
and is shown as % Control, DMSO treated wells. Negative control (Ctrl) was DMSO, while
Positive Ctrl 1 was BACE inhibitor IV and Positive Ctrl 2 was Compound E. (B) The
remaining cells were subjected to cell viability assay CellQuanti Blue. (C) Potent hits were
obtained from an independent source and subjected to IC50 determination in the 96-well
platform for Aβ40 biogenesis (Amiridine, 6.29 μM; Icariin, 1.412 μM; Phenelzine, 0.2834
μM; Progesterone, 0.1746 μM) determined by Prism analysis log(inhibitor) vs. normalized
response curve fit with baseline level of Aβ40 subtracted. (D) Chemical structures of hit
compounds(E) Representative Western blot analysis of APP processing determined using
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immunoprecipitation of secreted fragments α and β from condition media. Full length APP
was determined in protein lysate using Western blot analysis with 6E10 antibody and CTFs
were detected using CTMaxi antibody. Neuronal β-tubulin was detected using TUJ1. (F,G)
Quantification of sAPPβ and sAPPα (H) Full length APP was quantified by Image J analysis
and normalized to tubulin (TUJ1). (I) Quantification of Aβ40 after treatment with indicated
compounds normalized to protein level. Shown are means and SEM (n=3).
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Figure 7. Disparity In Pharmacological Response of Hit Compounds Between Tg2576 ESNs and
Cell Lines
(A) Tg2576 ES cell derived neurons; Neuro2a cells stably overexpressing APPsw (N2a-
APPsw); Chinese hamster ovary cells stably overexpressing wild type APP and PS1 with the
ΔE9 mutation (CHO-APPPS1); and SH-SY5Y cells stably overexpressing GFP-BACE1 and
HA-tagged wild type APP (BGWT8) were plated in 96 well plates and treated with hit
compounds (10μM) for 6 hours after which media was harvested and tested for Aβ40
content which was normalized to DMSO treated cells for each type (% control). Absolute
values for control (DMSO) treated cells are Tg2576 ESNs: 129±29.2 pg/ml; N2a-APPsw:
346±50.7 pg/ml; CHO-APPPS1: 62.5±.7 pg/ml; and BGWT8: 28.8±6.4 pg/ml.
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